< BackResearch FacultyDavid Hinton, MD

David Hinton, MD

DH3

Division: neural-scaffolds

Professor of Pathology, Neurological Surgery, Ophthalmology; Gavin S. Herbert Professorship in Retinal Research; Associate Dean for Vision Science; Vice Chair for Research, Exam Committee Facilitator; Director, Dean's Research Scholars Program

Research Interests:

Dr. Hinton is a board certified Pathologist (Neuropathology) with over 20 years of experience evaluating the pathogenesis of blinding retinal disorders with a focus on age related macular degeneration (AMD). He is a founding member of the Beckman Macular Research Center, and is a leader in the organization of a national meeting each year to move forward the field of atrophic AMD research. He is widely known for his expertise in the biology of the retinal pigmented epithelium (RPE) and has developed novel methods for culture and differentiation of RPE cells in vitro, and the morphologic, molecular and functional evaluation of their polarized phenotype. He is very interested in determining basic mechanisms of AMD pathogenesis and evaluating them in animal models. Dr. Hinton has a particular interest in the role of the small heat shock protein alphaB crystallin and its multifunctional role in protecting the retina from effects of aging and oxidative stress. He has published over 300 peer reviewed papers, and is editor of Volume 1 (Basic Science) of the 5th Edition of RETINA (Stephen J Ryan MD, Editor in Chief; 2013). He is Co-PI on the “California Project to Cure Blindness”: a multi-institutional program funded by the California Institute for Regenerative Medicine (CIRM) to develop cellular therapies for atrophic AMD. This project has established methods for differentiation of human embryonic stem cells to pure populations of RPE that can be grown as polarized sheets for subretinal transplantation. He has recently been funded as Co-PI by CIRM to perform a Phase 1 clinical trial for transplantation of stem cell-derived RPE on a non-biodegradable substrate in AMD patients with geographic atrophy. Dr Hinton is also interested in the pathology of demyelination and the role of immune cells and mediators in its pathogenesis.

Biography:

David R. Hinton, MD is the Gavin S. Herbert Professor of Retinal Research and Professor of Pathology, Neurological Surgery, and Ophthalmology at the Keck School of Medicine at the University of Southern California, Los Angeles; and Vice Chair of Academic and Research Affairs in the Department of Pathology at the Keck Hospital of USC. He graduated from the University of Toronto with a medical degree in 1978. He then completed a combined residency/fellowship program in neuropathology at the University of Toronto in 1983. He also completed a research fellowship at the prestigious California Institute of technology. Dr. Hinton has won several “Outstanding Teacher” awards through his mentorship of undergraduate and graduate students. He has won several “Outstanding Teacher” awards through his mentorship of both undergraduate and graduate students. Remarkably, Dr. Hinton has authored over 400 peer reviewed articles, abstracts and book chapters.

List of Publications:

  • Sreekumar PG, Chothe P, Sharma KK, Baid R, Kompella U, Spee C, Kannan N, Manh C, Ryan SJ, Ganapathy V, Kannan R, Hinton DR. Antiapoptotic properties of alpha-crystallin-derived peptide chaperones and characterization of their uptake transporters in RPE cells. Invest Ophthalmol Vis Sci 2013 ;54:2787-2798.
  • Zhou P, Kannan R, Spee C, Sreekumar PG, Dou G, Hinton DR. Protection of retina by αB crystallin in sodium iodate induced retinal degeneration. PLoS ONE 2014 May 29;9(5):e98275.
  • Fowler BJ, Gelfand BD, Kim Y, Kerur N, Tarallo V, Hirano Y, Amarnath S, Fowler DH, Radwan M, Young MT, Pittman K, Kubes P, Agarwal HK, Parang KA, Hinton DR, Bastos-Carvalho A, LiS, Yasuma T, Mizutani T, Yasuma R, Wright C, Ambati J. Nucleside revers transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science 2014; 346: 1000-1003.
  • Hirano Y, Yasuma T, Mizutani T, Fowler BJ, Tarollo V, Yasuma R, Kim Y, Bastos-Carvalho A, Kerur N, Gelfand BD, Bogdanovich S, He S, Zhang X, Nozaki M, Ijima R, Kaneko H, Ogura Y, Terasaki H, Nagai H, Haro I,Nunez G, Ambati BK, Hinton DR, Ambati J. IL18 is not therapeutic for neovascular age-related macular degeneration. Nature Medicine 2014; 20, 1372-1375.

Education:

  • MD Medicine – University of Toronto, Ontario, Canada, 1978
  • FRCP(C) Neuropathology – University of Toronto, Ontario, Canada, 1983
  • Postdoctoral Research Fellowship, University of Toronto, Ontario, Canada, 1978 – 1979

Other web profiles:

http://pibbs.usc.edu/faculty/profile/?fid=226profiles.sc-ctsi.org/david.hinton